Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo …
S Bonnick, T De Villiers, A Odio… - The Journal of …, 2013 - academic.oup.com
Context: Odanacatib (ODN) is a selective cathepsin K inhibitor being developed to treat
osteoporosis. Objective: The effects of ODN were evaluated on bone mineral density (BMD) …
osteoporosis. Objective: The effects of ODN were evaluated on bone mineral density (BMD) …
Odanacatib, effects of 16-month treatment and discontinuation of therapy on bone mass, turnover and strength in the ovariectomized rabbit model of osteopenia
Odanacatib (ODN) a selective and reversible cathepsin K inhibitor, inhibits bone resorption,
increases bone mass and reduces fracture risk in women with osteoporosis. A 16-month (~ 7 …
increases bone mass and reduces fracture risk in women with osteoporosis. A 16-month (~ 7 …
Odanacatib, a selective cathepsin K inhibitor, demonstrates comparable pharmacodynamics and pharmacokinetics in older men and postmenopausal women
MS Anderson, IN Gendrano, C Liu… - The Journal of …, 2014 - academic.oup.com
Background: Odanacatib is a cathepsin K inhibitor in development for the treatment of
osteoporosis. Evaluation of therapies to ensure that treatment effects are relevant regardless …
osteoporosis. Evaluation of therapies to ensure that treatment effects are relevant regardless …
Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study
B Langdahl, N Binkley, H Bone… - Journal of Bone and …, 2012 - academic.oup.com
Odanacatib (ODN) is a selective inhibitor of the collagenase cathepsin K that is highly
expressed by osteoclasts. In this 2‐year, phase 2, dose‐ranging trial, postmenopausal …
expressed by osteoclasts. In this 2‐year, phase 2, dose‐ranging trial, postmenopausal …
Implications of osteoblast-osteoclast interactions in the management of osteoporosis by antiresorptive agents denosumab and odanacatib
NA Sims, KW Ng - Current osteoporosis reports, 2014 - Springer
Antiresorptive agents, used in the treatment of osteoporosis, inhibit either osteoclast
formation or function. However, with these approaches, osteoblast activity is also reduced …
formation or function. However, with these approaches, osteoblast activity is also reduced …
Effect of odanacatib on BMD and fractures: estimates from Bayesian univariate and bivariate meta-analyses
O Gajic-Veljanoski, G Tomlinson… - The Journal of …, 2014 - academic.oup.com
Context: Odanacatib (ODN), a selective cathepsin-K inhibitor, was found to increase bone
mineral density (BMD); the effect on fractures is based on adverse event reports. Objective …
mineral density (BMD); the effect on fractures is based on adverse event reports. Objective …
Discontinuation of odanacatib and other osteoporosis treatments: here today and gone tomorrow?
DC Bauer - Journal of Bone and Mineral Research, 2011 - academic.oup.com
The options available for effective osteoporosis treatment continue to grow.(1) Because of
the large number of treatment options, many clinicians, particularly in primary care, are …
the large number of treatment options, many clinicians, particularly in primary care, are …
A Mild Inhibition of Cathepsin K Paradoxically Stimulates the Resorptive Activity of Osteoclasts in Culture
Cathepsin K (CatK) inhibition allows reducing bone resorption with specific advantages
compared to the existing anti-osteoporosis drugs. Its clinical use appears even more …
compared to the existing anti-osteoporosis drugs. Its clinical use appears even more …
Odanacatib restores trabecular bone of skeletally mature female rabbits with osteopenia but induces brittleness of cortical bone: a comparative study of the …
Cathepsin K (CK), a lysosomal cysteine protease, is highly expressed in mature osteoclasts
and degrades type 1 collagen. Odanacatib (ODN) is a selective and reversible CK inhibitor …
and degrades type 1 collagen. Odanacatib (ODN) is a selective and reversible CK inhibitor …
Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys
PJ Masarachia, BL Pennypacker… - Journal of Bone and …, 2012 - academic.oup.com
Odanacatib (ODN) is a selective and reversible inhibitor of cathepsin K (CatK) currently
being developed as a once‐weekly treatment for osteoporosis. In this study, we evaluated …
being developed as a once‐weekly treatment for osteoporosis. In this study, we evaluated …